Data to be presented at the American Thoracic Society Meeting May 2019 as a Late Breaker.
To examine the safety and preliminary efficacy of multiple adjunctive host directed TB therapies (TB HDT), to assess their potential to shorten TB treatment and/or prevent permanent lung damage.
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 2HRbEZ/4HRb
2HRbZE
|
Drug: 2HRbZE/4HRb
Other Name: rifabutin-modified TB therapy
|
| Experimental: Everolimus
Everolimus 0.5 MG
|
Drug: Everolimus 0.5 MG Drug: 2HRbZE/4HRb
Other Name: rifabutin-modified TB therapy
|
| Experimental: Auranofin
Auranofin 6 MG
|
Drug: Auranofin 6 MG Drug: 2HRbZE/4HRb
Other Name: rifabutin-modified TB therapy
|
| Experimental: Vitamin D
Vitamin D3 5 mg -> 2.5 mg
|
Drug: Vitamin D3 Drug: 2HRbZE/4HRb
Other Name: rifabutin-modified TB therapy
|
| Experimental: CC-11050
CC-11050 200 mg BID
|
Drug: CC-11050 Drug: 2HRbZE/4HRb
Other Name: rifabutin-modified TB therapy
|
Registry Link